Millennium Pharmaceuticals, Inc. Product Pipeline …SAMPLE Millennium Pharmaceuticals, Inc. – Product Pipeline Review Millennium Pharmaceuticals, Inc. – Product Pipeline Review

SAMPLE

Millennium Pharmaceuticals, Inc. – Product Pipeline Review – 2013 GMDHC03730CDB / Published MAY 2013

© Global Markets Direct. This report is a licensed product and is not to be photocopied Page(1)

Millennium Pharmaceuticals, Inc. – Product Pipeline

Review – 2013

Reference Code: GMDHC03730CDB

Publication Date: MAY 2013

SAMPLE


Review



Table of Contents

Table of Contents ............................................................................................................................................................................... 2

List of Tables ................................................................................................................................................................................. 6

List of Figures ................................................................................................................................................................................ 7

Millennium Pharmaceuticals, Inc. Snapshot ....................................................................................................................................... 8

Millennium Pharmaceuticals, Inc. Overview .................................................................................................................................. 8

Key Information ............................................................................................................................................................................. 8

Key Facts....................................................................................................................................................................................... 8

Millennium Pharmaceuticals, Inc. – Research and Development Overview ....................................................................................... 9

Key Therapeutic Areas .................................................................................................................................................................. 9

Millennium Pharmaceuticals, Inc. – Pipeline Review ........................................................................................................................ 13

Pipeline Products by Stage of Development ............................................................................................................................... 13

Pipeline Products – Monotherapy ............................................................................................................................................... 14

Pipeline Products – Combination Treatment Modalities .............................................................................................................. 15

Millennium Pharmaceuticals, Inc. – Pipeline Products Glance ......................................................................................................... 16

Millennium Pharmaceuticals, Inc. – Late Stage Pipeline ............................................................................................................. 16

Registration Filed Products/Combination Treatment Modalities.............................................................................................. 16

Filing Rejected/Withdrawn Products/Combination Treatment Modalities ................................................................................ 17

Phase III Products/Combination Treatment Modalities ........................................................................................................... 18

Millennium Pharmaceuticals, Inc. Clinical Stage Pipeline Products ............................................................................................. 19

Phase II Products/Combination Treatment Modalities ............................................................................................................ 19

Phase I Products/Combination Treatment Modalities ............................................................................................................. 20

Millennium Pharmaceuticals, Inc. – Early Stage Pipeline Products ............................................................................................. 21

Pre-Clinical Products/Combination Treatment Modalities ....................................................................................................... 21

Millennium Pharmaceuticals, Inc. – Drug Profiles ............................................................................................................................ 22

alisertib ........................................................................................................................................................................................ 22

Product Description ................................................................................................................................................................. 22

Mechanism of Action ............................................................................................................................................................... 22

R&D Progress ......................................................................................................................................................................... 22

alisertib + [paclitaxel] ................................................................................................................................................................... 23



R&D Progress ......................................................................................................................................................................... 23

bortezomib ................................................................................................................................................................................... 24



R&D Progress ......................................................................................................................................................................... 24

Bortezomib + Dexamethasone .................................................................................................................................................... 28



R&D Progress ......................................................................................................................................................................... 28

ixazomib citrate ............................................................................................................................................................................ 29


SAMPLE

Millennium Pharmaceuticals, Inc. – Product Pipeline Review


©Global Markets Direct.. This report is a licensed product and is not to be photocopied Page(3)


R&D Progress ......................................................................................................................................................................... 29

MLN-0128 .................................................................................................................................................................................... 32



R&D Progress ......................................................................................................................................................................... 32

MLN-0264 .................................................................................................................................................................................... 34



R&D Progress ......................................................................................................................................................................... 34

MLN-1117 .................................................................................................................................................................................... 35



R&D Progress ......................................................................................................................................................................... 35

MLN-2480 .................................................................................................................................................................................... 36



R&D Progress ......................................................................................................................................................................... 36

orteronel ...................................................................................................................................................................................... 37



R&D Progress ......................................................................................................................................................................... 37

pevonedistat ................................................................................................................................................................................ 39



R&D Progress ......................................................................................................................................................................... 39

TAK-733 ...................................................................................................................................................................................... 40



R&D Progress ......................................................................................................................................................................... 40

Velcade + Dexamethasone + Cyclophosphamide ....................................................................................................................... 41



R&D Progress ......................................................................................................................................................................... 41

Velcade + Dexamethasone + Cyclophosphamide + Revlimid ..................................................................................................... 43



R&D Progress ......................................................................................................................................................................... 43

Velcade + Dexamethasone + Revlimid ........................................................................................................................................ 45



R&D Progress ......................................................................................................................................................................... 45

Velcade + Thalidomide + Dexamethasone .................................................................................................................................. 47


SAMPLE





R&D Progress ......................................................................................................................................................................... 47

Millennium Pharmaceuticals, Inc. – Pipeline Analysis ...................................................................................................................... 49

Millennium Pharmaceuticals, Inc. – Pipeline Products by Therapeutic Class .............................................................................. 49

Millennium Pharmaceuticals, Inc. – Pipeline Products by Route of Administration...................................................................... 50

Millennium Pharmaceuticals, Inc. – Pipeline Products By Mechanism of Action ......................................................................... 51

Millennium Pharmaceuticals, Inc. – Recent Pipeline Updates ......................................................................................................... 53

Millennium Pharmaceuticals, Inc. - Dormant Projects ...................................................................................................................... 74

Millennium Pharmaceuticals, Inc. - Discontinued Pipeline Products ................................................................................................ 75

Discontinued Pipeline Product Profiles ........................................................................................................................................ 75

alisertib.................................................................................................................................................................................... 75

bortezomib .............................................................................................................................................................................. 75

TAK-441 .................................................................................................................................................................................. 75

TAK-448 .................................................................................................................................................................................. 76

TAK-701 .................................................................................................................................................................................. 76

TAK-901 .................................................................................................................................................................................. 76

TAK-960 .................................................................................................................................................................................. 76

tandutinib ................................................................................................................................................................................ 76

Millennium Pharmaceuticals, Inc. – Locations And Subsidiaries ...................................................................................................... 77

Head Office.................................................................................................................................................................................. 77

Millennium Pharmaceuticals, Inc., Recent Developments ................................................................................................................ 78

Millennium Pharmaceuticals, Inc.- Press Release ....................................................................................................................... 78

May 23, 2013: Takeda Initiates TOURMALINE-MM2 Pivotal Phase III Trial Of MLN9708 In Patients With Newly Diagnosed Multiple Myeloma .................................................................................................................................................................... 78

Apr 07, 2013: Millennium Pharma Presents Data From Meta-Analysis Of Velcade Phase III Trial At 14th International Myeloma Workshop ................................................................................................................................................................ 78

Dec 09, 2010: Millennium Reports Phase III Results Of VELCADE Combination Therapy In Multiple Myeloma .................... 80

Dec 09, 2010: Millennium Reports Positive Results From Phase III Trial With VELCADE Based Induction Regimens In Multiple Myeloma .................................................................................................................................................................... 81

Dec 07, 2010: Millennium Reports Phase III Study Final Positive Results Of VELCADE In Combination With Rituximab In Follicular Lymphoma ............................................................................................................................................................... 82

Dec 07, 2010: Millennium Reports Phase III Trial Results Of VELCADE In Multiple Myeloma ............................................... 83

Dec 06, 2010: Millennium Reports Encouraging Phase I Results Of MLN4924 In Acute Myeloid Leukemia .......................... 84

Nov 30, 2010: Intellikine And MMRC Initiate Phase I Trial Of Multiple Myeloma Drug ........................................................... 84

Nov 10, 2010: Velcade Induction And Maintenance Data TO Be Featured In Oral Presentations At American Society Of Hematology Annual Meeting ................................................................................................................................................... 85

Nov 04, 2010: Millennium And Takeda Announce Advancement Of Prostate Cancer Program ............................................. 86

Sep 02, 2010: Millennium Announces Publication Of MLN4924 Preclinical Activity In Lymphoma In Blood ........................... 86

Jul 29, 2010: Millennium Reports Data From Pinnacle Trial Of Velcade In Patients With Relapsed/Refractory Mantle Cell Lymphoma .............................................................................................................................................................................. 87

Jun 07, 2010: Millennium Presents New Clinical Data On MLN9708 For Treatment Of Solid Tumors At ASCO 2010 Meeting ................................................................................................................................................................................................ 88

Jun 07, 2010: Millennium Presents New Clinical Data On TAK-700 For Treatment Of Solid Tumors At ASCO 2010 Meeting ................................................................................................................................................................................................ 88

Jun 07, 2010: Millennium Presents Phase I Clinical Data Of TAK-701 For Treatment Of Solid Tumors At ASCO 2010 Meeting ................................................................................................................................................................................... 89

Jun 07, 2010: Millennium Presents Phase I Data On MLN8237 For Treatment Of Solid Tumors At ASCO 2010 Meeting ..... 89

SAMPLE




Jun 04, 2010: Millennium Presents Velcade Data On Relapsed Or Refractory Amyloidosis At American Society of Clinical Oncology Annual Meeting ....................................................................................................................................................... 90

May 10, 2010: Takeda To Co-promote VELCADE For Injection In Japan .............................................................................. 91

Mar 09, 2010: Millennium Announces First Clinical Data For TAK-700 Prostate Molecule At ASCO GU ............................... 92

Jan 15, 2010: Takeda Oncology Announces Publication Of Millenium's Enzyme Inhibitor MLN4924 In The Molecular Cell Journal .................................................................................................................................................................................... 92

Jan 05, 2010: Intellikine Initiates Phase I Clinical Trial Of INK128 For The Prevention Of Cancer ......................................... 93

Jan 05, 2010: Takeda Receives Additional Approval Of Velcader (Bortezomib) For The Treatment Of Multiple Myeloma .... 94

Jan 04, 2010: The Addition of VELCADE (Bortezomib) for Injection to Novel Combination Delivers Promising Results in Patients With Non-Hodgkin‘s Lymphoma ................................................................................................................................ 94

Jan 04, 2010: FDA Approves Addition Of Sustained Overall Survival Benefit To Label For Velcade (Bortezomib) Injection For Patients With Previously Untreated Multiple Myeloma ............................................................................................................ 95

Financial Deals Landscape .............................................................................................................................................................. 97

Millennium Pharmaceuticals, Inc., Deals Summary ..................................................................................................................... 97

Millennium Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deal Details .............................................................................. 98

Partnerships ................................................................................................................................................................................ 98

Seattle Genetics And Millennium Pharma Enter Into Co-Development Agreement With Ventana Medical Systems.............. 98

Presage Biosciences Enters Into Co-Development Agreement With Millennium Pharma For Cancer Drugs ......................... 99

Millenium: The Takeda Oncology Enters Into Research Collaboration With Therasis .......................................................... 100

Seattle Genetics Enters Into Co-Development Agreement With Millennium ......................................................................... 102

Millennium Enters Into Co-Development Agreement With Harvard Medical School ............................................................. 104

Licensing Agreements ............................................................................................................................................................... 105

Infinity Pharma Amends Licensing Agreement With Millennium Pharma .............................................................................. 105

Millennium Enters Into Licensing Agreement With Sunesis Pharma ..................................................................................... 107

Seattle Genetics Extends Licensing Agreement With Millennium ......................................................................................... 109

Seattle Genetics Enters Into Licensing Agreement With Millennium Pharma ....................................................................... 110

Trigen Enters Into Licensing Agreement With Millennium Pharma ....................................................................................... 111

Debt Offering ............................................................................................................................................................................. 112

Millennium Pharma Completes Public Offering Of 2.25% Senior Notes For US$250 Million ................................................ 112

Acquisition ................................................................................................................................................................................. 114

Takeda Acquires Millennium Pharma For US$8.8 Billion ...................................................................................................... 114

Appendix ........................................................................................................................................................................................ 116

Methodology .............................................................................................................................................................................. 116

Coverage ................................................................................................................................................................................... 116

Secondary Research ................................................................................................................................................................. 116

Primary Research ...................................................................................................................................................................... 116

Expert Panel Validation ............................................................................................................................................................. 116

Disclaimer .................................................................................................................................................................................. 117

SAMPLE




List of Tables

Millennium Pharmaceuticals, Inc., Key Information ............................................................................................................................ 8

Millennium Pharmaceuticals, Inc., Key Facts ..................................................................................................................................... 8

Millennium Pharmaceuticals, Inc. – Pipeline by Indication, 2013 ..................................................................................................... 10

Millennium Pharmaceuticals, Inc. – Pipeline by Stage of Development, 2013 ................................................................................. 13

Millennium Pharmaceuticals, Inc. – Monotherapy Products in Pipeline, 2013 .................................................................................. 14

Millennium Pharmaceuticals, Inc. – Combination Treatment Modalities in Pipeline, 2013 ............................................................... 15

Millennium Pharmaceuticals, Inc. – Filed, 2013 ............................................................................................................................... 16

Millennium Pharmaceuticals, Inc. – Filing Rejected/Withdrawn, 2013 .............................................................................................. 17

Millennium Pharmaceuticals, Inc. – Phase III, 2013 ......................................................................................................................... 18

Millennium Pharmaceuticals, Inc. – Phase II, 2013 .......................................................................................................................... 19

Millennium Pharmaceuticals, Inc. – Phase I, 2013 ........................................................................................................................... 20

Millennium Pharmaceuticals, Inc. – Pre-Clinical, 2013 ..................................................................................................................... 21

Millennium Pharmaceuticals, Inc. – Pipeline By Therapeutic Class, 2013........................................................................................ 49

Millennium Pharmaceuticals, Inc. – Pipeline By Route of Administration, 2013 ............................................................................... 50

Millennium Pharmaceuticals, Inc. – Pipeline Products By Mechanism of Action, 2013 .................................................................... 52

Millennium Pharmaceuticals, Inc. – Recent Pipeline Updates, 2013 ................................................................................................ 53

Millennium Pharmaceuticals, Inc. - Dormant Developmental Projects,2013..................................................................................... 74

Millennium Pharmaceuticals, Inc. - Discontinued Pipeline Products, 2013 ...................................................................................... 75

Millennium Pharmaceuticals, Inc., Deals Summary .......................................................................................................................... 97

Seattle Genetics And Millennium Pharma Enter Into Co-Development Agreement With Ventana Medical Systems ....................... 98

Presage Biosciences Enters Into Co-Development Agreement With Millennium Pharma For Cancer Drugs .................................. 99

Millenium: The Takeda Oncology Enters Into Research Collaboration With Therasis .................................................................... 100

Seattle Genetics Enters Into Co-Development Agreement With Millennium .................................................................................. 102

Millennium Enters Into Co-Development Agreement With Harvard Medical School ....................................................................... 104

Infinity Pharma Amends Licensing Agreement With Millennium Pharma ....................................................................................... 105

Millennium Enters Into Licensing Agreement With Sunesis Pharma .............................................................................................. 107

Seattle Genetics Extends Licensing Agreement With Millennium .................................................................................................. 109

Seattle Genetics Enters Into Licensing Agreement With Millennium Pharma................................................................................. 110

Trigen Enters Into Licensing Agreement With Millennium Pharma ................................................................................................. 111

Millennium Pharma Completes Public Offering Of 2.25% Senior Notes For US$250 Million ......................................................... 112

Takeda Acquires Millennium Pharma For US$8.8 Billion ............................................................................................................... 114

SAMPLE




List of Figures

Millennium Pharmaceuticals, Inc. – Pipeline by Indication, 2013 .................................................................................................... 10

Millennium Pharmaceuticals, Inc. – Pipeline by Stage of Development, 2013 ................................................................................ 13

Millennium Pharmaceuticals, Inc. – Monotherapy Products in Pipeline, 2013 .................................................................................. 14

Millennium Pharmaceuticals, Inc. – Combination Treatment Modalities in Pipeline, 2013 ............................................................... 15

Millennium Pharmaceuticals, Inc. – Pipeline By Route of Administration, 2013 .............................................................................. 50

Millennium Pharmaceuticals, Inc. - Pipeline Products By Mechanism of Action, 2013 .................................................................... 51

SAMPLE


Review



Millennium Pharmaceuticals, Inc. Snapshot

Millennium Pharmaceuticals, Inc. Overview

Millennium Pharmaceuticals, Inc. (Millennium) is a bio pharmaceutical company that undertakes research, development, and

commercialization activities of medicines used for the treatment of cancer. The company develops drugs related to inflammation.

Millennium is a subsidiary of Takeda Pharmaceutical Company Limited. The company‘s lead product, Velcade (bortezomib), is

used to treatment multiple myeloma and Mantle Cell Lymphoma. Millennium has 300 projects under way with pipeline products of

more than 15 oncology investigational compounds that targets diseases like, growth signaling inhibition, angiogenesis, protein

homeostasis, apoptosis, cell cycle inhibition and hormone regulation.

Key Information

Millennium Pharmaceuticals, Inc., Key Information

Web Address

Financial year-end:

No. of Employees

Source: Global Markets Direct

Key Facts

Millennium Pharmaceuticals, Inc., Key Facts

Corporate Address

Telephone No. of Employees

Fax Fiscal Year End

URL Revenue (in USD Million)

Industry


SAMPLE




Millennium Pharmaceuticals, Inc. – Research and Development Overview

Key Therapeutic Areas

SAMPLE




Millennium Pharmaceuticals, Inc. – Pipeline Review

Pipeline Products by Stage of Development

Millennium Pharmaceuticals, Inc. – Pipeline by Stage of Development, 2013


Millennium Pharmaceuticals, Inc. – Pipeline by Stage of Development, 2013

Late Stage Products (Filed/Filing

Rejected/Withdrawn/Phase III)

Clinical Stage

Products(Phase II/Phase I)

Early Stage Products (Pre-

Clinical/Discovery)

Status

Unknown


SAMPLE




Pipeline Products – Monotherapy

Millennium Pharmaceuticals, Inc. – Monotherapy Products in Pipeline, 2013


Millennium Pharmaceuticals, Inc. – Monotherapy Products in Pipeline, 2013



Clinical Stage



Clinical/Discovery)

Status

Unknown


SAMPLE




Pipeline Products – Combination Treatment Modalities

Millennium Pharmaceuticals, Inc. – Combination Treatment Modalities in Pipeline, 2013


Millennium Pharmaceuticals, Inc. – Combination Treatment Modalities in Pipeline, 2013



Clinical Stage



Clinical/Discovery)

Status

Unknown


SAMPLE




Millennium Pharmaceuticals, Inc. – Pipeline Products Glance

Millennium Pharmaceuticals, Inc. – Late Stage Pipeline

Registration Filed Products/Combination Treatment Modalities

Millennium Pharmaceuticals, Inc. – Filed, 2013

Product Name Therapeutic Class Route of Administration Target


--N/A--: Not Available

SAMPLE




Filing Rejected/Withdrawn Products/Combination Treatment Modalities

Millennium Pharmaceuticals, Inc. – Filing Rejected/Withdrawn, 2013




SAMPLE




Phase III Products/Combination Treatment Modalities

Millennium Pharmaceuticals, Inc. – Phase III, 2013




SAMPLE




Millennium Pharmaceuticals, Inc. Clinical Stage Pipeline Products

Phase II Products/Combination Treatment Modalities

Millennium Pharmaceuticals, Inc. – Phase II, 2013




SAMPLE




Phase I Products/Combination Treatment Modalities

Millennium Pharmaceuticals, Inc. – Phase I, 2013




SAMPLE




Millennium Pharmaceuticals, Inc. – Early Stage Pipeline Products

Pre-Clinical Products/Combination Treatment Modalities

Millennium Pharmaceuticals, Inc. – Pre-Clinical, 2013




SAMPLE




Millennium Pharmaceuticals, Inc. – Drug Profiles

alisertib

Product Description

Mechanism of Action

R&D Progress

SAMPLE




alisertib + [paclitaxel]

Product Description

Mechanism of Action

R&D Progress

SAMPLE




Millennium Pharmaceuticals, Inc. – Pipeline Analysis

Millennium Pharmaceuticals, Inc. – Pipeline Products by Therapeutic Class

Millennium Pharmaceuticals, Inc. – Pipeline By Therapeutic Class, 2013

Therapeutic

Class

Filed Phase I Phase II Phase III Pre-Clinical Total


SAMPLE




Millennium Pharmaceuticals, Inc. – Pipeline Products by Route of Administration

Millennium Pharmaceuticals, Inc. – Pipeline By Route of Administration, 2013


Millennium Pharmaceuticals, Inc. – Pipeline By Route of Administration, 2013

Route of

Administratio

n

Filed Phase I Phase II Phase III Pre-Clinical TOTAL


SAMPLE




Millennium Pharmaceuticals, Inc. - Dormant Projects

Millennium Pharmaceuticals, Inc. - Dormant Developmental Projects,2013

Product Name Stage of Development IndicationName Therapeutic Class


SAMPLE




Millennium Pharmaceuticals, Inc. - Discontinued Pipeline Products

Millennium Pharmaceuticals, Inc. - Discontinued Pipeline Products, 2013

Product Name Year of Discontinuation Stage of Discontinuation


Discontinued Pipeline Product Profiles

alisertib

bortezomib

TAK-441

SAMPLE




Financial Deals Landscape

Millennium Pharmaceuticals, Inc., Deals Summary

Millennium Pharmaceuticals, Inc., Deals Summary

Deal Date Deal Status Deal Type Acquirer (s) / Investor (s)

/Surviving Entity

Target / Issuer / Partner (s)

Vendor Deal Value (US $ million)

SOURCE: Global Markets Direct

Note: Deals include all announced deals with disclosed deal values from 2004 onwards

SAMPLE




Millennium Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deal Details

Partnerships

Seattle Genetics And Millennium Pharma Enter Into Co-Development Agreement With Ventana Medical

Systems

Seattle Genetics And Millennium Pharma Enter Into Co-Development Agreement With Ventana Medical Systems

Deal Type Deal Sub Type

Deal in Brief

Deal Rationale

Deal Information

Deal Status

Completed Date

Companies Information

Partner Company Information

Company Name

Business Description

Company Name Parent


Company Name Parent


Deal Product

brentuximab vedotin



SAMPLE




Presage Biosciences Enters Into Co-Development Agreement With Millennium Pharma For Cancer Drugs

Presage Biosciences Enters Into Co-Development Agreement With Millennium Pharma For Cancer Drugs

Deal Type Deal Sub Type

Deal in Brief

Deal Rationale

Deal Information

Deal Status

Completed Date

Companies Information

Partner Company Information

Company Name


Company Name Parent




SAMPLE

Appendix



Appendix

Methodology

Global Markets Direct dedicated Research and Analysis Teams consists of experienced professionals with a pedigree

in marketing, market research, consulting background in the pharmaceutical industry and advanced statistical

expertise.

Global Markets Direct adheres to the Codes of Practice of the Market Research Society (www.mrs.org.uk) and the

Strategic and Competitive Intelligence Professionals (www.scip.org).

All Global Markets Direct databases are continuously updated and revised. The following research methodology is

followed for all databases and reports.

Coverage

The objective of updating Global Markets Direct coverage is to ensure that it represents the most up to date vision of

the industry possible.

Changes the industry taxonomy are built on the basis of extensive research of company, association and competitor

sources.Company coverage is based on three key factors: market capitalization, revenues and media

attention/innovation/ market potential.An exhaustive search of 56 member exchanges is conducted and companies

are prioritized on the basis of their market capitalization.The estimated revenues of all major companies, including

private and governmental, are gathered and used to prioritize coverage.Companies which are making the news, or

which are of particular interest due to their innovative approach are prioritized.Global Markets Direct aims to cover all

major news events and deals in the pharmaceutical industry, updated on a daily basis.The coverage is further

streamlined and strengthened with additional inputs from Global Markets Direct Expert Panel (see below).

Secondary Research

The research process begins with exhaustive secondary research on internal and external sources being carried out

to source qualitative and quantitative information relating to each market.The secondary research sources that are

typically referred to include, but are not limited to:Company websites, annual reports, financial reports, broker reports,

investor presentations and SEC FilingsIndustry trade journals and other literatureInternal and external proprietary

databasesNational government documents, statistical databases and market reportsNews articles, press releases

and web-casts specific to the companies operating in the market

Primary Research

Global Markets Direct conducts hundreds of primary interviews a year with industry participants and commentators in

order to validate its data and analysis. A typical research interview fulfills the following functions:It provides first-hand

information on the market size, market trends, growth trends, competitive landscape, future outlook etcHelps in

validating and strengthening the secondary research findingsFurther develops the Analyses Team‘s expertise and

market understandingPrimary research involves E-mail interactions, telephonic interviews as well as face-to-face

interviews for each market, category, segment and sub-segment across geographies.The participants who typically

take part in such a process include, but are not limited to:Industry participants: CEOs, VPs, business development

managers, market intelligence managers and national sales managersOutside experts: Investment Bankers,

Valuation Experts, Research Analysts and key opinion leaders specializing in pharmaceutical industry

Expert Panel Validation

Global Markets Direct uses a panel of experts to cross verify research and forecast methodologies, and drive its

analytical content.The Global Markets Direct expert panel comprises of marketing managers, product specialists,

international sales managers from pharmaceutical companies; academics from research universities and consultants

from professional services companies. Details of the make up of the expert panel can be viewed through website, and

are available to clients on request.

SAMPLE

Appendix



Disclaimer

All Rights Reserved.

No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form by any means,

electronic, mechanical, photocopying, recording or otherwise, without the prior permission of the publisher, Global

Markets Direct

Documents

Millennium Pharmaceuticals, Inc. Product Pipeline …SAMPLE Millennium Pharmaceuticals, Inc. – Product Pipeline Review Millennium Pharmaceuticals, Inc. – Product Pipeline Review